A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are
effective in treating children with Central Precocious Puberty (CPP).